Exelixis Inc. Stock
Exelixis Inc. Stock
A loss of -2.600% shows a downward development for Exelixis Inc..
The stock is an absolute favorite of our community with 40 Buy predictions and no Sell predictions.
As a result the target price of 40 € shows a slightly positive potential of 7.82% compared to the current price of 37.1 € for Exelixis Inc..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Exelixis Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Exelixis Inc. in the next few years
Pros
?
B****
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
C******** o* t** e**********
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Exelixis Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Exelixis Inc. | -2.600% | 0.079% | 7.934% | 12.327% | 16.697% | 144.889% | 144.763% |
| Ironwood Pharmaceuticals | 0.000% | -12.048% | 63.128% | -7.006% | -30.476% | -74.164% | -70.355% |
| Novocure Ltd | 1.730% | -6.222% | 10.076% | -60.710% | -64.286% | -85.491% | -91.736% |
| Iovance Biotherapeutics Inc. | 5.220% | -11.285% | -5.009% | -77.935% | -72.702% | -72.690% | -95.094% |
Comments
Exelixis (NASDAQ:EXEL) had its price target raised by analysts at TD Cowen from $44.00 to $51.00. They now have a "buy" rating on the stock.
Show more
Ratings data for EXEL provided by MarketBeat
Exelixis (NASDAQ:EXEL) had its price target raised by analysts at Morgan Stanley from $44.00 to $45.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for EXEL provided by MarketBeat
Exelixis (NASDAQ:EXEL) had its price target raised by analysts at HC Wainwright from $46.00 to $49.00. They now have a "buy" rating on the stock.
Show more
Ratings data for EXEL provided by MarketBeat
News
The Ultimate Biotech Stock to Buy With $50 Right Now
Finding great biotech stocks to invest in at a price point of $50 per share (or less) isn't easy. There are plenty of companies in the industry trading for far less money than that, but they tend to
Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years
Every investor wants to outperform the market, but it's a challenging feat to achieve. That's why few manage to do it consistently over long periods. What's the best approach to take? Day trading is
Exelixis Stock: Mixed Signals After Earnings Beat
Biotech company Exelixis delivered notably mixed second-quarter 2025 results, creating divergent investor reactions. The California-based firm reported earnings per share of $0.75, significantly
